Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained an Outperform rating on Dianthus Therapeutics (NASDAQ:DNTH) and increased the price target from $34 to $51.
April 18, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has reaffirmed its Outperform rating on Dianthus Therapeutics and raised the price target from $34 to $51.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong bullish outlook on the stock, suggesting that the firm believes DNTH has significant upside potential from its current price level. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100